Cartalax

Cartalax is an investigational peptide studied for cartilage and connective-tissue support. Tissue repair and recovery are research interests, but it has no FDA approval.

• Tissue Repair

  Most effective

  Research investigates faster wound closure and repair of damaged soft tissue.

• Gut Health

  Effective

  Potential gastrointestinal effects include support for intestinal lining integrity and digestive function.

• Joint Support

  Effective

  Joint-related research examines lower inflammation together with better mobility.

• Muscle Recovery

  Moderate

  Possible benefits include quicker recovery from muscle strains and stress associated with exercise.

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

• TB-500 / BPC-157 (stack)

  Compatible

• NSAIDs (Ibuprofen, Naproxen)

  Caution

• Corticosteroids

  Caution

• Anticoagulants

  Monitor

• GH Secretagogues

  Compatible

• NAD+

  Compatible

Diluent: Use bacteriostatic water only; avoid saline because it may cause precipitation.

1. Take the Cartalax vial out of the refrigerator and leave it for 15–20 minutes to reach room temperature.
2. Disinfect the vial stopper with an alcohol swab. Wait until the alcohol has completely air-dried.
3. Measure the calculated amount of bacteriostatic water into a sterile syringe. Use only bacteriostatic water; avoid saline because precipitation may occur.
4. Add the water slowly along the inner wall of the vial. Keep the stream away from the powder itself.
5. Rotate the vial gently to mix its contents. Never shake it vigorously, because this can degrade the peptide.
6. Wait 2–3 minutes for the powder to dissolve completely. Check that the liquid is clear and has no color.
7. Withdraw the calculated dose into an insulin syringe for administration beneath the skin.
8. Inject into your abdomen, thigh or upper arm. Change the injection site each time to help prevent lipodystrophy.
9. Refrigerate the mixed solution at 2–8 °C. Use it within 28 days after reconstitution.

Week 1–2

Early anti-inflammatory effects may reduce pain and swelling around the affected tissue.

Week 2–4

Tissue mobility may improve as discomfort decreases and healing begins to progress more rapidly.

Week 4–8

Recovery may reach more substantial milestones, with better tissue repair and improved function.

Week 8–12

Later expectations include near-complete healing in many cases, increased strength and better tissue integrity. These intervals are research expectations, not established individual outcomes.

• Mild nausea, especially with larger doses
• Redness or soreness at the injection site
• Lightheadedness or dizziness · Rare
• Possible changes in blood pressure; monitor your pressure if you have hypertension

Cartalax: not approved in the US.

• US

  Not approved

  FDA — research use only; no approval.

  Rx required

  No

  503A

  Allowed

  Telehealth

  N/A

1. Cartilage bioregulatory peptide in osteoarthritis models (preclinical review) (2014)

2. Peptide bioregulation of aging: results and prospects. (2010)

   PMID 19830585DOI 10.1007/s10522-009-9249-8